Expert speakers include:

  • ChristophBaumgaertel, AGES, Austria Christoph Baumgaertal
    Assessor
    AGES, Austria
  • MarcusBrewster,  Pharmaceutical Research, Johnson & Johnson, Belgium Marcus Brewster
    Distinguished Research Fellow
    Pharmaceutical Research, Johnson & Johnson, Belgium
  • Thomas Kerbusch, Merck/MSD, The NetherlandsThomas Kerbusch
    Senior Director, Technical Lead Innovation, Implementation & Impact of Modeling & Simulation
    Merck/MSD, The Netherlands

Speed time to market by ensuring regulatory compliance, biowaiver approval and successful bioequivalence studies for modified release products

The bioequivalence approval process is now faster, easier and cheaper than ever before but are you taking full advantage of these benefits to ensure that your products reach the market as quickly and cost effectively as possible?

Pharma IQ’s 2nd Annual Bioequivalence and Bioavailability Studies conference will highlight the challenges and successes of the 2010 EMA guidelines, outline effective strategies for ensuring compliance, provide practical case studies on optimising study design, increasing biowaiver success rate to speed time to market and decrease costs as well as providing in-depth insights into the future challenges of modified release products.

Download the brochure here for all the details and full speaker line up.

podcast Top Podcast

Helmut Schutz and Anders Fuglsang

One Year On: The Bioequivalence Guidelines
Helmut Schuetz of BEBAC Consultancy and Anders Fuglsang of Fuglsang Pharma Consultancy, join Pharma IQ to discuss the impact of the bioequivalence guidelines introduced in summer 2010 on the pharmaceutical industry.

Top 10 Reasons to Attend

1. Receive regulatory clarification of the bioequivalence submission criteria to ensure compliance and speed time to market

2. Be prepared for the new modified release guidelines

3. Make informed decisions before starting your studies through effective use of in vitro testing and establishing IVIVC

4. Optimise study design by understanding the two stage approach

5. Successfully secure a biowaiver with tips from the regulators and clarification of the biopharmaceutical classification system

6. Overcome the challenges of establishing bioequivalence for highly variable drugs

7. Address the implications for industry of the draft bioanalytical guidelines

8. Translate results to clinical relevance using modelling and stimulation tools

9. Interactive roundtable sessions - gain further in-depth knowledge in your chosen subject area

10. Interact and network with your colleagues and peers in our dedicated networking sessions!

Testimonials

Very good to hear the assessor's views on the subject.
Abbott
Media Partners
_media